Globus Medical Files 8-K Reporting Other Events

TL;DR

Globus Medical filed an 8-K for 'Other Events' on July 16, 2024. Details TBD.

AI Summary

Globus Medical, Inc. filed an 8-K on July 16, 2024, reporting other events. The filing does not contain specific details about the nature of these events, dollar amounts, or other named entities beyond the company itself.

Why It Matters

This filing indicates that Globus Medical has reported an event requiring disclosure to the SEC, though the specifics are not detailed in the provided text.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' without immediate disclosed financial impact or significant corporate changes.

Key Players & Entities

• GLOBUS MEDICAL, INC. (company) — Registrant
• July 16, 2024 (date) — Date of earliest event reported
• DELAWARE (jurisdiction) — State of incorporation
• 2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403-5214 (address) — Principal executive offices

FAQ

Filing Documents

• gmed-20240716x8k.htm (8-K) — 68KB
• 0001562762-24-000209.txt ( ) — 180KB
• gmed-20240716.xsd (EX-101.SCH) — 2KB
• gmed-20240716_lab.xml (EX-101.LAB) — 12KB
• gmed-20240716_pre.xml (EX-101.PRE) — 11KB
• gmed-20240716x8k_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events . On July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the "FDA") following an inspection of our facilities in Audubon, Pennsylvania. In the warning letter, the FDA cited deficiencies in the response letters sent by the Company to the FDA following the Form 483, List of Investigational Observations, which was delivered to the Company in connection with the inspection that occurred from February 15, 2024 until March 7, 2024. The letter describes observed non-conformities in establishing and maintaining product complaint procedures, including complaint investigations, trending, risk reconciliation, and Medical Device Report (MDR) procedures including timely reporting, pertaining to the ExcelsiusGPS robotic system. The letter does not identify any safety concerns with the use of the ExcelsiusGPS robotic system, nor does it raise any issue with our manufacturing process. We take the matters identified in the warning letter seriously and have taken corrective actions and provided a comprehensive and timely response to the FDA. We believe the FDA's concerns set forth in the warning letter have been or can be resolved without a material impact to our operations or financial results. We cannot, however, give any assurances that the FDA will be satisfied with our response or as to the expected date of the resolution of the matters included in the warning letter. Until the issues cited in the warning letter are resolved to the FDA's satisfaction, additional legal or regulatory action may be taken without further notice. Safe Harbor Statements

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GLOBUS MEDICAL, INC. (Registrant) Dated: August 13, 2024 /s/ KEITH PFEIL Keith Pfeil Chief Financial Officer and Chief Operating Officer Chief Accounting Officer Executive Vice President (Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR